J B K Sun Pharma India Profile
Key Indicators
- Authorised Capital ₹ 0.70 M
- Paid Up Capital ₹ 0.10 M
- Company Age 22 Year, 9 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 0.50 M
About J B K Sun Pharma India
J B K Sun Pharma India Private Limited (JBKSPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 May 2002 and has a history of 22 years and nine months. Its registered office is in Delhi, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.70 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Meera Singhal and Priyanka Singhal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231DL2002PTC115355
- Company No.
115355
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 May 2002
- Date of AGM
30 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does J B K Sun Pharma India Private Limited offer?
J B K Sun Pharma India Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Diabetic Herbal Medicine, Ayurvedic & Herbal Health Supplement, Herbal Juice, Ayurvedic Medicine, Common Disease Medicines, Pharmaceutical Capsules, Cosmetics, Hair & Beauty Products, Henna Powder.
Who are the key members and board of directors at J B K Sun Pharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meera Singhal  | Director | 14-May-2005 | Current |
| Priyanka Singhal | Director | 13-Jan-2010 | Current |
Financial Performance of J B K Sun Pharma India.
J B K Sun Pharma India Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of J B K Sun Pharma India?
In 2017, J B K Sun Pharma India had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Oct 2020 | Hdfc Bank Limited | ₹0.50 M | Open |
How Many Employees Work at J B K Sun Pharma India?
Unlock and access historical data on people associated with J B K Sun Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of J B K Sun Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped J B K Sun Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
